Goelzer Investment Management Inc. Acquires 628 Shares of Boston Scientific Co. (NYSE:BSX)

Goelzer Investment Management Inc. increased its holdings in Boston Scientific Co. (NYSE:BSX) by 1.8% during the 4th quarter, HoldingsChannel.com reports. The firm owned 35,337 shares of the medical equipment provider’s stock after purchasing an additional 628 shares during the period. Goelzer Investment Management Inc.’s holdings in Boston Scientific were worth $3,156,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of BSX. Evergreen Capital Management LLC lifted its holdings in Boston Scientific by 28.4% in the second quarter. Evergreen Capital Management LLC now owns 5,950 shares of the medical equipment provider’s stock valued at $458,000 after buying an additional 1,315 shares during the period. Armistice Capital LLC acquired a new position in shares of Boston Scientific during the second quarter valued at about $1,794,000. APG Asset Management N.V. increased its holdings in Boston Scientific by 31.6% during the 2nd quarter. APG Asset Management N.V. now owns 1,292,296 shares of the medical equipment provider’s stock worth $92,857,000 after purchasing an additional 310,101 shares in the last quarter. Ameriprise Financial Inc. grew its holdings in Boston Scientific by 30.0% during the second quarter. Ameriprise Financial Inc. now owns 7,899,610 shares of the medical equipment provider’s stock worth $608,349,000 after buying an additional 1,824,405 shares in the last quarter. Finally, Dark Forest Capital Management LP raised its holdings in shares of Boston Scientific by 60.0% in the second quarter. Dark Forest Capital Management LP now owns 5,130 shares of the medical equipment provider’s stock valued at $395,000 after purchasing an additional 1,924 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Evercore ISI lifted their price target on Boston Scientific from $82.00 to $90.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Sanford C. Bernstein lifted their target price on Boston Scientific from $92.00 to $100.00 and gave the stock an “outperform” rating in a research note on Thursday, October 24th. JPMorgan Chase & Co. raised their price objective on shares of Boston Scientific from $100.00 to $110.00 and gave the stock an “overweight” rating in a report on Monday, December 16th. Morgan Stanley boosted their target price on shares of Boston Scientific from $92.00 to $100.00 and gave the company an “overweight” rating in a research note on Thursday, October 24th. Finally, TD Cowen raised their price target on shares of Boston Scientific from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Thursday, December 12th. Three analysts have rated the stock with a hold rating, twenty have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $97.26.

Insider Activity

In other news, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $90.78, for a total transaction of $633,916.74. Following the completion of the sale, the executive vice president now owns 29,308 shares in the company, valued at approximately $2,660,580.24. This trade represents a 19.24 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP John Bradley Sorenson sold 4,119 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $90.02, for a total transaction of $370,792.38. Following the completion of the transaction, the executive vice president now owns 35,319 shares in the company, valued at approximately $3,179,416.38. This trade represents a 10.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 29,989 shares of company stock worth $2,702,261 in the last three months. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Stock Up 0.3 %

BSX stock opened at $101.97 on Friday. Boston Scientific Co. has a twelve month low of $59.97 and a twelve month high of $102.15. The firm has a market capitalization of $150.29 billion, a PE ratio of 84.28, a PEG ratio of 2.63 and a beta of 0.80. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. The stock has a 50-day simple moving average of $91.96 and a two-hundred day simple moving average of $85.16.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.59 by $0.04. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. The business had revenue of $4.21 billion for the quarter, compared to analyst estimates of $4.04 billion. During the same quarter in the prior year, the firm posted $0.50 EPS. Boston Scientific’s revenue was up 19.3% on a year-over-year basis. On average, equities analysts predict that Boston Scientific Co. will post 2.46 EPS for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.